The announcement is set to come a month after the company found that its shot, which is already authorized for those age 16 and older, also provided protection for the younger group.
The federal official, speaking on the condition of anonymity to preview the FDA's action, revealed the agency was expected to expand its emergency use authorization for Pfizer's two-dose vaccine by early next week, and perhaps even sooner. The person familiar with the process, who spoke on condition of anonymity to discuss internal matters, confirmed the timeline and added that it is expected that the FDA will approve Pfizer's use by even younger children sometime this fall.
The FDA action will be followed by a meeting of a federal vaccine advisory committee to discuss whether to recommend the shot for 12- to 15-year-olds. Vaccines could begin after the Centers for Disease Control and Prevention adopts the committee's recommendation. Those steps could be completed in a matter of days.
WATCH: SPEAKER JOHNSON CALLS ON COLUMBIA UNIVERSITY PRESIDENT TO RESIGN
The New York Times unveiled the expected timing for the authorization.
Pfizer in late March released preliminary results from a vaccine study of 2,260 U.S. volunteers ages 12 to 15, showing there were no cases of COVID-19 among fully vaccinated adolescents compared with 18 among those given dummy shots.
A CRYING SHAME: PRO-PALESTINIAN PROTESTS FORCE USC TO CANCEL PRIMARY GRADUATION EVENT
Kids had side effects similar to young adults, the company noted. The main side effects include pain, fever, chills and fatigue, particularly after the second dose. The study will continue to track participants for two years for more information on the long-term protection and safety.
WATCH GREAT ANALYSIS: THE ABSURDITY OF ANTI-ISRAEL PROTESTS
Pfizer isn't the only company seeking to lower the age limit for its vaccine. Results also are expected by the middle of this year from a U.S. study of Moderna's vaccine in 12- to 17-year-olds.
REPUBLICAN SENATORS EXPOSE DARK SIDE OF 'FOOD DELIVERY' ECONOMICS
Indicating that the findings were promising, the FDA already allowed both companies to begin U.S. studies in children 11 and younger, working their way to as young as 6 months old.
Over 131 million doses of Pfizer's vaccine have already been administered in the U.S., where demand for vaccines among adults has dramatically slowed in recent weeks.
AMERICA'S BIRTHRATE CONTINUES TO PLUMMET - ARE MILLENNIALS TRADING DIAPERS FOR DEGREES?
While younger people are at vastly lower risk of serious side effects from COVID-19, they have made up a larger share of new virus cases as a majority of U.S. adults have been at least partially vaccinated and as higher-risk activities like indoor dining and contact sports have resumed in most of the country. Officials hope that extending vaccinations to teens will further accelerate the nation's reduced virus caseload and allow schools to reopen with minimal disruptions this fall.
The U.S. has ordered at least 300 million doses of the Pfizer shot by the end of July, enough to protect 150 million people.
Discover alternative ideas that will make you think
Engage in mind bending debate
Earn points, rise in rank, have fun
